SCHEMBL165024

SCHEMBL165024

O=C=Nc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.48
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 2/20 0.45
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 2/20 0.44
HSD17B10 Q99714 1/20 0.44
CA2 P00918 5/20 0.42
CA1 P00915 3/20 0.42
TRPA1 O75762 1/20 0.38
EPHX2 P34913 1/20 0.36
CYP1A2 P05177 1/20 0.36
PTGS1 P23219 2/20 0.33
PTGS2 P35354 2/20 0.33
CA9 Q16790 4/20 0.31
CA12 O43570 2/20 0.31
POLB P06746 1/20 0.31
CYP2D6 P10635 1/20 0.31
CA5A P35218 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
CA7 P43166 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL278353 0.82 CYP3A4 (0.52) CYP3A4TSHRTDP1MAPK1ALDH1A1
SCHEMBL7180551 0.82 CYP3A4 (0.52) CYP3A4TSHRTDP1MAPK1ALDH1A1
SCHEMBL8694424 0.81 CA1 (0.66) CYP3A4TDP1ALDH1A1HSD17B10CA2
SCHEMBL3044709 0.78 CYP3A4 (0.48) CYP3A4TSHRTDP1MAPK1CA2
SCHEMBL242025 0.78 CA2 (0.68) CYP3A4TSHRTDP1CA2CA1
SCHEMBL31148855 0.78 CYP3A4 (0.48) CYP3A4TSHRTDP1MAPK1ALDH1A1
SCHEMBL2278953 0.78 POLB (0.53) CYP3A4TSHRTDP1MAPK1ALDH1A1
SCHEMBL10348147 0.78 CYP3A4 (0.48) CYP3A4TSHRTDP1MAPK1ALDH1A1
SCHEMBL13651653 0.78 TDP1 (0.41) CYP3A4TSHRTDP1MAPK1ALDH1A1
SCHEMBL15430 0.78 CYP3A4 (0.70) CYP3A4TSHRTDP1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365056-B2 Substituted 9a-N-(N′-(sulfonyl)phenylcarbamoyl)derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithomycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9-a-aza-9a-homoerithronolide A GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O (HR) 2008-04-29 US claimed
EP-1575969-B1 SUBSTITUTED 9a-N-(N'- 4-(SULFONYL)PHENYL CARBAMOYL) DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-0-DESOSAMINYL-9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HOMOERITHRONOLIDE A PLIVA ISTRAZIVACKI INST D D O (HR) 2006-07-12 EP claimed
US-20060084795-A1 Substituted 9a-n-[n'-(benzenesulfonyl)carbamoyl-aminopropyl]and 9a-n-[n'-(b-cya-neothyl) -n-[n'-(benzenesulfonyl)carbamoyl-y-aminopropyl]derivatives of 9-deoxo-9-dihydro-9a-aza- 9a-homoerithromycin a and 5-0-aza-homoerithronolide a PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-04-20 US claimed
EP-1575969-A1 SUBSTITUTED 9a-N-(N'- 4-(SULFONYL)PHENYL CARBAMOYL) DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-0-DESOSAMINYL-9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HOMOERITHRONOLIDE A Pliva-Istrazivacki Institut D.D.O. (HR) 2005-09-21 EP claimed
WO-2004043985-A1 SUBSTITUTED 9A-N-{N'-[4-(SULFONYL)PHENYL]CARBAMOYL} DERIVATIVES OF 9-DEOXO-9-DIHYDRO-9A-AZA-9A-HOMOERITHROMYCIN A AND 5-0-DESOSAMINYL­-9-DEOXO-9-DI-HYDRO-9A-AZA-9A-HOMOERITHRONOLIDE A PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (HR) 2004-05-27 WO claimed
EP-0154811-A2 Coupling agents between mineral fillers and polymers Plüss-Staufer AG (CH) 1985-09-18 EP claimed
WO-1985003505-A2 COUPLING AGENT BETWEEN MINERAL FILLERS AND POLYMERS PLÜSS-STAUFER AG (CH) 1985-08-15 WO claimed
CN-121260915-A Electrolyte and lithium ion battery 江苏国轩新能源科技有限公司 2026-01-02 CN disclosed
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 EP disclosed
EP-4464727-A1 ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-11-20 EP disclosed
US-20240300968-A1 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES UNIV MANCHESTER (GB) 2024-09-12 US disclosed
EP-4377300-A1 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES The University of Manchester (GB) 2024-06-05 EP disclosed
US-20240150515-A1 Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers COVESTRO DEUTSCHLAND AG (DE) 2024-05-09 US disclosed
US-4342869-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-08-03 US disclosed
US-4338437-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-07-06 US disclosed
US-4338438-A Cephalosporin antibiotics MERCK & CO., INC. (US) 1982-07-06 US disclosed
US-4324890-A ANTIBIOTICS, BACTERICIDES MERCK & CO., INC. (US) 1982-04-13 US disclosed
US-4297488-A 7-α-Methoxy cephalosporins MERCK & CO., INC. (US) 1981-10-27 US disclosed
US-4086209-A Novel nitrogen-containing aromatic polymers and process for their preparation TEIJIN LIMITED (JA) 1978-04-25 US disclosed
US-4031068-A Non-migratory sulfonyl azide antioxidants UNIROYAL INC. (US) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300968-A1 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES NAPRT, NAMPT, NUDT1 CYP3A4 3331/4885TSHR 3228/4885TDP1 2294/4885
US-20060084795-A1 Substituted 9a-n-[n'-(benzenesulfonyl)carbamoyl-aminopropyl]and 9a-n-[n'-(b-cya-neothyl) -n-[n'-(benzenesulfonyl)carbamoyl-y-aminopropyl]derivatives of 9-deoxo-9-dihydro-9a-aza- 9a-homoerithromycin a and 5-0-aza-homoerithronolide a HEXA, HINT1, CDA CYP3A4 806/4885TSHR 3140/4885TDP1 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.